In addition, AS-IV inhibited intestinal FXR signaling, reduced intestinal FGF15 expression, thereby reducing liver FXR activation, increased glucagon-like peptide-1 secretion, and ultimately suppressed SREBP-1c-mediated lipogenesis and liver steatosis (Zhai et al., 2022). This evidence concerns the gene NR1H4 and medical procedure.